Evidence map›Paper›PMID 38687384›Full record

ArticleLung2024

Endobronchial Ultrasound Guided Transbronchial Needle Aspiration and Next Generation Sequencing Yields.

Kristin N Sheehan, Lara M Khoury, Angela G Niehaus, William I Mariencheck, Katherine A Gershner, Travis L Dotson, Christina R Bellinger

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lung, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Liquid biopsy in lung cancer.Breathe (Sheffield, England) · 2025
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kristin N SheehanDepartment of Pulmonary/Critical Care, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA. Knsheeha@wakehealth.edu.
Lara M KhouryDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA.
Angela G NiehausDepartment of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA.
William I MariencheckDepartment of Pulmonary/Critical Care, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA.
Katherine A GershnerDepartment of Pulmonary/Critical Care, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA.
Travis L DotsonDepartment of Pulmonary/Critical Care, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA.
Christina R BellingerDepartment of Pulmonary/Critical Care, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA.

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
NCI NIH HHS P30 CA012197
6 · The paper itself

Abstract

purposeThe use of endobronchial ultrasound (EBUS) is standard practice for lung cancer diagnosis and staging. Next generation sequencing (NGS) for detection of genetic alterations is recommended in advanced, non-squamous, non-small-cell lung cancer (NSCLC). Existing protocols for NGS testing are minimal and reported yields vary. This study aimed to determine the yield of EBUS samples obtained for NGS using a sampling protocol at our institution and assess predictive factors to form collection protocols.

methodsWe reviewed EBUS bronchoscopies from 2016 to 2021 with non-squamous NSCLC diagnoses. For target lesions suspected to be malignant, the sampling protocol was: (a) two slides for on-site evaluation, (b) three to five fine needle aspirations rinsed into saline for immunohistochemical staining and in-house molecular markers, and (c) additional three to five rinses for NGS. Sufficiency for NGS processing was determined by the pathology department.

resultsTwo hundred and seventy-eight non-squamous NSCLC samples were obtained by EBUS (205 adenocarcinoma; 73 not otherwise specified). EBUS was performed under general anesthesia in 75.5% of cases. The overall sample adequacy for NGS testing was 57.5%. Higher adequacy rates were observed when protocol was adhered to 66.0% versus 37.2% (p < 0.001). There was no statistically significant difference based on the size of the lesion or location of the sample.

conclusionWhen a protocol of three to five dedicated needle rinses for NGS was followed, we nearly doubled our sample adequacy rate for NSG as compared to standard care. Studies are needed to determine the ideal collection and processing modality to preserve tissue samples for genetic sequencing.

Indexed as

BronchoscopyCarcinoma, Non-Small-Cell LungEndoscopic Ultrasound-Guided Fine Needle AspirationHigh-Throughput Nucleotide SequencingLung NeoplasmsAdenocarcinoma of LungAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesBronchoscopyEBUS-TBNALung cancerMolecular markersNext generation sequencing

Identifiers

PMID38687384
PMCPMC11143046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.